Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2013.49.1118PMID 23669224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acquired and inherited risk factors for the developing of venous thromboembolism in cancer patients receiving adjuvant chemotherapy: A prospective trial.

  2016cited by this paper
• Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE): Awareness and Prophylaxis Practices Reported by Patients with Cancer

  2015cited by this paper
• Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.

  2014influential reference
• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

  2014cited by this paper
• Incidence and predictors of venous thromboembolism (VTE) among ambulatory high‐risk cancer patients undergoing chemotherapy in the United States

  2013cited by this paper
• Apixaban for extended treatment of venous thromboembolism.

  2013cited by this paper
• Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study)

  2013cited by this paper
• [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism].

  2013cited by this paper
• Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial

  2012cited by this paper
• Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

  2012cited by this paper
• Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads

  2012cited by this paper
• Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.

  2012cited by this paper
• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

  2012cited by this paper
• Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

  2012cited by this paper
• Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer

  2012cited by this paper
• Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis

  2012cited by this paper
• Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis

  2012cited by this paper
• SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations)

  2012cited by this paper
• Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer

  2012cited by this paper
• A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system

  2012cited by this paper
• Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

  2012cited by this paper
• Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

  2012cited by this paper
• Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients

  2012cited by this paper
• Risk assessment for cancer-associated thrombosis: what is the best approach?

  2012cited by this paper
• A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer

  2012cited by this paper
• A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score

  2012cited by this paper
• Is Incidentally Detected Pulmonary Embolism in Cancer Patients Less Severe? A Case-Control Study

  2012cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2011cited by this paper
• [Cancer, thromboembolia and antithrombotic therapy: is there an anticoagulant of choice?].

  2011cited by this paper
• High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis.

  2011cited by this paper
• Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.

  2011influential reference
• The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study.

  2011cited by this paper
• Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation.

  2011cited by this paper
• Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center

  2011cited by this paper
• Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.

  2011cited by this paper
• Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients.

  2011cited by this paper
• No accumulation of the peak anti‐factor Xa activity of tinzaparin in elderly patients with moderate‐to‐severe renal impairment: the IRIS substudy

  2011cited by this paper
• Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer

  2011cited by this paper
• Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.

  2011influential reference
• Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi‐row detector computed tomography scanning

  2011cited by this paper
• Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS).

  2011cited by this paper
• Center

  2011cited by this paper
• Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.

  2011cited by this paper
• Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006

  2010cited by this paper
• Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial.

  2010cited by this paper
• Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC‐2 studies

  2010influential reference
• Cancer Patients and Awareness of Venous Thromboembolism

  2010cited by this paper
• An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN

  2010cited by this paper
• Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.

  2010cited by this paper
• A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial.

  2010cited by this paper
• High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients

  2010cited by this paper
• The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery

  2010cited by this paper
• Comparison of characteristics from White‐ and Black‐Americans with venous thromboembolism: A cross‐sectional study

  2010cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2010cited by this paper
• Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation.

  2010cited by this paper
• PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma

  2010cited by this paper
• Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study.

  2010cited by this paper
• Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study

  2010cited by this paper
• A Validation Study of a Retrospective Venous Thromboembolism Risk Scoring Method

  2010cited by this paper
• Prediction of venous thromboembolism in cancer patients.

  2010cited by this paper
• Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility

  2010influential reference
• A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study

  2010cited by this paper
• Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis.

  2010cited by this paper
• Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma.

  2010cited by this paper
• Comparison of characteristics from White‐ and Black‐Americans with venous thromboembolism: A cross sectional study

  2010cited by this paper
• Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

  2009cited by this paper
• Assessing risk of venous thromboembolism in the patient with cancer.

  2009cited by this paper
• Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.

  2009cited by this paper
• Effects of race and ethnicity on the incidence of venous thromboembolism.

  2009cited by this paper
• Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition)

  2009cited by this paper
• Prevention of venous thromboembolism in hospitalized patients with cancer.

  2009cited by this paper
• Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients

  2009cited by this paper
• Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.

  2009cited by this paper
• Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials

  2009cited by this paper
• Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)

  2008cited by this paper
• Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.

  2008influential reference
• Extended perioperative thromboprophylaxis in patients with cancer

  2008cited by this paper
• Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

  2008cited by this paper
• Efficacy of extended thrombo-prophylaxis in major abdominal surgery: What does the evidence show?

  2008cited by this paper
• Development and validation of a predictive model for chemotherapy-associated thrombosis.

  2008cited by this paper
• Rates of venous thromboembolism occurrence in medical patients among the insured population

  2008cited by this paper
• Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients

  2008cited by this paper
• Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer

  2008cited by this paper
• Knowledge of venous thromboembolism (VTE) prevention among hospitalized patients.

  2008cited by this paper
• Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis.

  2008cited by this paper
• Racial and Ethnic Disparities in U.S. Health Care: A Chartbook

  2008cited by this paper
• Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review.

  2007cited by this paper
• A Systematic Review of Deep Venous Thrombosis Prophylaxis in Cancer Patients: Implications for Improving Quality

  2007cited by this paper
• A meta‐analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment

  2007cited by this paper
• The management of venous thromboembolism in cancer patients.

  2007cited by this paper
• Guideline : Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

  2007cited by this paper
• Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.

  2007cited by this paper
• Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study

  2006cited by this paper
• Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.

  2006cited by this paper
• A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery: The @RISTOS Project

  2006cited by this paper
• Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency

  2006cited by this paper
• A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer

  2006cited by this paper
• Risk factors for venous thromboembolic events in cancer patients.

  2006cited by this paper
• Dosage of enoxaparin among obese and renal impairment patients.

  2005cited by this paper
• Eight-Year Follow-Up of Patients With Permanent Vena Cava Filters in the Prevention of Pulmonary Embolism: The PREPIC (Prévention du Risque d’Embolie Pulmonaire par Interruption Cave) Randomized Study

  2005cited by this paper

• Macrocytosis as an Early Pharmacodynamic Marker of Imatinib Efficacy in Chronic Myeloid Leukemia

  2026cites this paper
• Multiple Ischemic Strokes Associated with Pulmonary Embolism Revealing Occult Pulmonary Adenocarcinoma: About Two (2) Cases and Review of the Literature

  2026cites this paper
• Concomitant pulmonary embolism and severe thrombocytopenia associated with an APS-like autoimmune thrombophilic condition: a case report.

  2026cites this paper
• Management of Classic Hodgkin Lymphoma in Pregnancy.

  2026cites this paper
• Determining the perceptions and practices of oncologists regarding venous thromboembolism risk assessment in ambulatory cancer patients: A qualitative study

  2025cites this paper
• Assessing the Comparative Efficacy and Safety of Warfarin and Rivaroxaban for Cancer Associated Thrombosis: Experience From a Resource Limited Setting

  2025cites this paper
• Venous thromboembolism risk in newly diagnosed lymphoma patients: a real-world prospective observational study from Vietnam National Cancer Hospital

  2025cites this paper
• Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis

  2025cites this paper
• Bibliometric Analysis of Non-Vitamin K Antagonist Oral Anticoagulants (NOACS) in the Prevention of Venous Thrombosis and Pulmonary Embolism

  2025cites this paper
• Review of Trousseau phenomenon - pathomechanism, diagnosis, treatment and risk of cancer

  2025cites this paper
• Risk Assessment Models for Venous Thromboembolism in Gynecological Patients: A Review of Current Practices and Future Directions

  2025cites this paper
• Breaking the barriers to VTE prevention in ambulatory cancer patients. When implementation strategy comes into play

  2024cites this paper
• Clinical guidelines for prevention and treatment of CAT in Japan and other countries

  2024cites this paper
• Deep Vein Thrombosis Prophylaxis in Orthopedic Surgery

  2024cites this paper
• Updated review on malignancy-associated venous thromboembolism: Pathogenesis and comparison between various therapeutic modalities

  2024cites this paper
• The performance of Khorana risk score for prediction of venous thromboembolism in patients with lung cancer: A retrospective cohort study

  2024cites this paper
• Effectiveness and safety of rivaroxaban or low-molecular-weight heparin in non-major orthopedic surgery: a meta-analysis of randomized controlled trials

  2024cites this paper
• Incidence, Risk Factors, and Modified Risk Assessment Model of Venous Thromboembolism in Non‐Hodgkin Lymphoma Patients

  2024cites this paper
• The Role of Anticoagulation on Venous Thromboembolism Primary Prophylaxis in Low- to Intermediate-Risk Ambulatory Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• Fertility preservation in lymphoma patients treated with immunochemotherapy regimens with or without radiotherapy: results of a retrospective multicenter Italian study (Ferty care)

  2024cites this paper
• Extended-duration thromboprophylaxis following major abdominopelvic surgery - For everyone or selected cases only?

  2024cites this paper
• Modeling cancer-associated hypercoagulability using glioblastoma spheroids in microfluidic chips

  2024cites this paper
• 64-Year-Old Female With Right Upper Quadrant Pain and Jaundice.

  2023cites this paper
• Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer.

  2023cites this paper
• Apixaban for Extended Thromboprophylaxis After Oncologic Resection: Outcomes and Cost Analysis

  2023cites this paper
• A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

  2023cites this paper
• Design of an Ultralow Molecular Weight Heparin That Resists Heparanase Biodegradation.

  2023cites this paper
• Development and validation of a predictive nomogram for lower extremity deep vein thrombosis dislodgement in orthopedic patients

  2023cites this paper
• Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants.

  2023cites this paper
• Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update

  2023cites this paper
• Changes in Coagulation in Cancer Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Treatment (HIPEC)—A Systematic Review

  2023cites this paper
• A prospective study to evaluate the use of surveillance venous ultrasonography to detect incidence of deep venous thrombosis following neurosurgical excision of brain tumors

  2023cites this paper
• Venous Thromboembolism Chemoprophylaxis Adherence Rates After Major Cancer Surgery

  2023cites this paper
• Cardio-oncology today: digest of the first European clinical guidelines (2022).

  2023cites this paper
• Persistent underuse of extended venous thromboembolism prophylaxis in patients undergoing major abdominal cancer operations

  2023cites this paper
• Optimal D-dimer cut-off values for diagnosing deep vein thrombosis in patients with comorbid malignancies.

  2023cites this paper
• Current Management of Cancer-Associated Thromboembolism in the Prophylactic and Acute Setting

  2023cites this paper
• Successful Model for Guideline Implementation to Prevent Successful Model for Guideline Implementation to Prevent Cancer-Associated Thrombosis: Venous Thromboembolism Cancer-Associated Thrombosis: Venous Thromboembolism Prevention in the Ambulatory Cancer Clinic Prevention in the Ambulatory Cancer C

  2023cites this paper
• Comparative Efficacy of Oral Apixaban and Subcutaneous Low Molecular Weight Heparins in the Treatment of Cancer-Associated Thromboembolism: A Meta-Analysis

  2023cites this paper
• Non-Vitamin K Antagonist Oral Anticoagulants versus Low Molecular Weight Heparin for Cancer-Related Venous Thromboembolic Events: Individual Patient Data Meta-Analysis

  2023cites this paper
• Improving outcomes of pancreatic surgery

  2023cites this paper
• Comparative Efficacy of Direct Oral Anticoagulants and Low-Molecular-Weight Heparin in Cancer-Associated Thromboembolism: A Systematic Review and Meta-Analysis

  2023cites this paper
• Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism

  2023cites this paper
• Thrombosis and Haemostasis Dynamic Patterns and Persistence of Anticoagulation Therapy in Patients with Venous Thromboembolism in South Korea: A Nationwide Cohort Study

  2023cites this paper
• Venous thromboembolism and bleeding after hepatectomy: role and impact of risk adjusted prophylaxis

  2023cites this paper
• The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study

  2022cites this paper
• Effect of Previous Anticoagulant Treatment on Risk of COVID-19

  2022cites this paper
• Cerebral Infarction Caused by Trousseau’s Syndrome Associated With Lung Cancer

  2022cites this paper
• Comparison of Performances among Four Bleeding-Prediction Scores in Elderly Cancer Patients with Venous Thromboembolism

  2022cites this paper
• Effect of low molecular weight heparin on bleeding after radical gastrectomy: A retrospective study from a high-volume center in China

  2022cites this paper
• Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis

  2022cites this paper
• Superior vena cava syndrome-induced hemoptysis.

  2022cites this paper
• New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism

  2022cites this paper
• Heparin mimetics as potential intervention for COVID-19 and their bio-manufacturing

  2022cites this paper
• Hemorrhagic Pericardial Effusion From Apixaban Use: Case Report and Literature Review

  2022cites this paper
• Bleeding and venous thromboembolism events in cancer patients taking direct oral anticoagulants vs. low molecular weight heparin

  2022cites this paper
• A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib

  2022cites this paper
• Assessing the use of Extended Venous Thromboembolism Prophylaxis on the Rates of Venous Thromboembolism and Postpancreatectomy Hemorrhage Following Pancreatectomy for Malignancy

  2022cites this paper
• Clinical epidemiology of venous thromboembolic disease: An institutional registry

  2022cites this paper
• Preoperative low-molecular weight heparin chemoprophylaxis in head and neck free flap reconstruction.

  2022cites this paper
• Thromboprophylaxis of cancer patients undergoing systemic therapy in the ambulatory setting.

  2022cites this paper
• Evaluation of the Khorana Predictive Thrombotic Risk and Thromboprophylaxis Score in Cancer Patients in a Third Level Hospital

  2022cites this paper
• Cancer‐associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study

  2022cites this paper
• Recurrent thrombosis rescued by fondaparinux in high‐risk patients: A case series

  2022cites this paper
• Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

  2022cites this paper
• Trousseau Syndrome in a 25-Year-Old Woman with Occult Colon Malignancy, Lynch Syndrome, and Chronic Thromboembolic Pulmonary Hypertension.

  2022cites this paper
• Validation of a modified Caprini risk assessment model in lung cancer patients undergoing surgery: Results of a multicenter cross‐sectional observational study

  2022cites this paper
• Prophylaxis extension for venous thromboembolism after major abdominal and pelvic surgery for cancer (prevent): Quality improvement transitioned into a cohort study.

  2022cites this paper
• Risk factors for venous thromboembolism in metastatic colorectal cancer with contemporary treatment: A SEER‐Medicare analysis

  2022cites this paper
• Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma

  2022cites this paper
• Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism.

  2022cites this paper
• Asymptomatic pulmonary thromboembolism diagnosed based on prolonged fever after gastric cancer surgery: A case report with literature review

  2022cites this paper
• IMPROVE bleeding score predicts major bleeding in advanced gastrointestinal cancer patients with venous thromboembolism.

  2022cites this paper
• Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma

  2022cites this paper
• Dynamic Patterns and Persistence of Anticoagulation Therapy in Patients with Venous Thromboembolism in South Korea: A Nationwide Cohort Study

  2022cites this paper
• Perioperative management in gynecological surgery based on the ERAS program

  2022cites this paper
• Rationale and design of a prospective, multicenter, cohort study on the evaluation of postoperative Venous ThromboEmbolism incidence in patients with ColoRectal Cancer (CRC-VTE trial)

  2021cites this paper
• Postoperative Pharmacologic Anticoagulation following Temporal Lobe Resection of a Gliosarcoma in a Hypercoagulable Patient

  2021cites this paper
• Perioperative Short Term Prophylaxis against Deep Vein Thrombosis after Major Abdominal Cancer Surgery: Retrospective Cohort Study

  2021cites this paper
• The Role of Factor Xa-Independent Pathway and Anticoagulant Therapies in Cancer-Related Stroke

  2021cites this paper
• Predictors of thrombosis in patients treated with bevacizumab

  2021cites this paper
• The American Society for Metabolic and Bariatric Surgery (ASMBS) updated position statement on perioperative venous thromboembolism prophylaxis in bariatric surgery.

  2021cites this paper
• Balancing Risk of Thromboembolism and Bleeding in Patients with Cancer: Selecting Anticoagulant Therapy Based on Recent Clinical Trials

  2021cites this paper
• Bioactive Natural Compounds with Antiplatelet and Anticoagulant Activity and Their Potential Role in the Treatment of Thrombotic Disorders

  2021cites this paper
• Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus

  2021cites this paper
• Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis

  2021cites this paper
• Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents.

  2021cites this paper
• Concurrence of Gastric Cancer and Incidental Pulmonary Embolism May Be a Prognostic Factor for Advanced Gastric Cancer Patients with Incidental Pulmonary Embolism

  2021cites this paper
• Treatment Toxicity

  2021cites this paper
• A Propensity-Matched Analysis of the Postoperative Venous Thromboembolism Rate After Pancreatoduodenectomy Based on Operative Approach

  2021cites this paper
• Postoperative bleeding and venous thromboembolism in colorectal cancer patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis

  2021cites this paper
• Optimal Medical Therapy Following Deep Venous Interventions: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel.

  2021cites this paper
• Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score

  2021cites this paper
• Direct Oral Anticoagulation in Cancer Patients

  2021cites this paper
• Pain management, fluid therapy and thromboprophylaxis after pancreatoduodenectomy: a worldwide survey among surgeons.

  2021cites this paper
• Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study

  2021cites this paper
• Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study

  2021cites this paper
• Concomitant central venous sinus thrombosis and subdural hematoma in acute promyelocytic leukemia: middle meningeal artery embolization enables safe anticoagulation. Illustrative case

  2021cites this paper
• Experimental Drugs for Chemotherapy- and Cancer-Related Anemia

  2021cites this paper
• Healthcare costs of patients with cancer stratified by Khorana score risk levels

  2021cites this paper